{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:09:56Z","timestamp":1792134596429,"version":"4.4.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Health & Welfare","award":["HI12C1852"],"award-info":[{"award-number":["HI12C1852"]}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Science, ICT & Future Planning","award":["2015R1C1A2A01053747"],"award-info":[{"award-number":["2015R1C1A2A01053747"]}]},{"name":"Ministry of Education","award":["2017R1A6A3A11029467"],"award-info":[{"award-number":["2017R1A6A3A11029467"]}]},{"DOI":"10.13039\/100016341","name":"Korea University Guro Hospital","doi-asserted-by":"crossref","award":["O1700571"],"award-info":[{"award-number":["O1700571"]}],"id":[{"id":"10.13039\/100016341","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.canlet.2017.10.020","type":"journal-article","created":{"date-parts":[[2017,11,5]],"date-time":"2017-11-05T17:46:12Z","timestamp":1509903972000},"page":"118-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer"],"prefix":"10.1016","volume":"412","author":[{"given":"Yoon-Jae","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daeil","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunhye","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngkwan","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Min","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Farrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hong","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2017.10.020_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"issue":"Suppl 2","key":"10.1016\/j.canlet.2017.10.020_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000055404","article-title":"HER2 as a prognostic factor in breast cancer","volume":"61","author":"Menard","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.canlet.2017.10.020_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2017.10.020_bib4","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signaling network: receptor heterodimerization in development and cancer","volume":"19","author":"Olayioye","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2017.10.020_bib5","doi-asserted-by":"crossref","first-page":"8933","DOI":"10.1073\/pnas.1537685100","article-title":"The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation","volume":"100","author":"Holbro","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2017.10.020_bib6","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1158\/0008-5472.CAN-08-0380","article-title":"A\u00a0central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy","volume":"68","author":"Lee-Hoeflich","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2017.10.020_bib7","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2017.10.020_bib8","first-page":"4744","article-title":"Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells","volume":"61","author":"Molina","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2017.10.020_bib9","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-04-0225","article-title":"Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2","volume":"10","author":"Gennari","year":"2004","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.canlet.2017.10.020_bib10","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0301-472X(99)00089-2","article-title":"Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2\/neu","volume":"27","author":"Cooley","year":"1999","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.canlet.2017.10.020_bib11","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.canlet.2017.10.020_bib12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.canlet.2017.10.020_bib13","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1634\/theoncologist.2008-0001","article-title":"Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Dahabreh","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2017.10.020_bib14","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1158\/1078-0432.CCR-09-0636","article-title":"Resistance to trastuzumab in breast cancer","volume":"15","author":"Pohlmann","year":"2009","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.canlet.2017.10.020_bib15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/1078-0432.CCR-05-1807","article-title":"p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer","volume":"12","author":"Saez","year":"2006","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.canlet.2017.10.020_bib16","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1158\/0008-5472.CAN-10-3795","article-title":"p95HER2 and breast cancer","volume":"71","author":"Arribas","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2017.10.020_bib17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","article-title":"ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome","volume":"1","author":"Ginestier","year":"2007","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2017.10.020_bib18","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1038\/onc.2008.207","article-title":"HER2 regulates the mammary stem\/progenitor cell population driving tumorigenesis and invasion","volume":"27","author":"Korkaya","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2017.10.020_bib19","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2017.10.020_bib20","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/jnci\/djn123","article-title":"Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy","volume":"100","author":"Li","year":"2008","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2017.10.020_bib21","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/jnci\/djj495","article-title":"The response of CD24(-\/low)\/CD44+ breast cancer-initiating cells to radiation","volume":"98","author":"Phillips","year":"2006","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2017.10.020_bib22","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","article-title":"Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer","volume":"23","author":"Buzdar","year":"2005","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2017.10.020_bib23","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2460\/ajvr.1983.44.07.1329","article-title":"Flubendazole: dose range and efficacy studies against common internal parasites of swine","volume":"44","author":"Bradley","year":"1983","journal-title":"Am. J. Veterinary Res."},{"key":"10.1016\/j.canlet.2017.10.020_bib24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/0035-9203(79)90018-X","article-title":"The anthelmintic effects of flubendazole on Brugia pahangi","volume":"73","author":"Denham","year":"1979","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.canlet.2017.10.020_bib25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/eri.11.30","article-title":"Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs","volume":"9","author":"Mackenzie","year":"2011","journal-title":"Expert Rev. Anti Infective Ther."},{"key":"10.1016\/j.canlet.2017.10.020_bib26","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.parint.2009.07.006","article-title":"Flubendazole in cystic echinococcosis therapy: pharmaco-parasitological evaluation in mice","volume":"58","author":"Ceballos","year":"2009","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.canlet.2017.10.020_bib27","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2009-09-243055","article-title":"The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma","volume":"115","author":"Spagnuolo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2017.10.020_bib28","doi-asserted-by":"crossref","first-page":"8202","DOI":"10.1038\/srep08202","article-title":"Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen","volume":"5","author":"Michaelis","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2017.10.020_bib29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/jphp.12503","article-title":"Flubendazole induces mitotic catastrophe and senescence in colon cancer cells in\u00a0vitro","volume":"68","author":"Kralova","year":"2016","journal-title":"J.\u00a0Pharm. Pharmacol."},{"key":"10.1016\/j.canlet.2017.10.020_bib30","doi-asserted-by":"crossref","first-page":"6326","DOI":"10.18632\/oncotarget.3436","article-title":"Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells","volume":"6","author":"Hou","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2017.10.020_bib31","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbamcr.2016.03.010","article-title":"Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis","volume":"1863","author":"Oh","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2017.10.020_bib32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.canlet.2016.11.022","article-title":"Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation","volume":"386","author":"Kim","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2017.10.020_bib33","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.bbrc.2017.03.164","article-title":"Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells","volume":"486","author":"Kim","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2017.10.020_bib34","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.cellsig.2017.05.009","article-title":"Inhibition of ubiquitin-specific protease 34 (USP34) induces epithelial-mesenchymal transition and promotes stemness in mammary epithelial cells","volume":"36","author":"Oh","year":"2017","journal-title":"Cell. Signal."},{"key":"10.1016\/j.canlet.2017.10.020_bib35","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.bbrc.2015.09.108","article-title":"Salinomycin possesses anti-tumor activity and inhibits breast cancer stem-like cells via an apoptosis-independent pathway","volume":"466","author":"An","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2017.10.020_bib36","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2017.10.020_bib37","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1535-7163.1585.3.12","article-title":"Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer","volume":"3","author":"Tanner","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2017.10.020_bib38","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1158\/1535-7163.MCT-09-1171","article-title":"Activated phosphoinositide 3-kinase\/AKT signaling confers resistance to trastuzumab but not lapatinib","volume":"9","author":"O'Brien","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2017.10.020_bib39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canlet.2016.05.026","article-title":"Disulfiram targets cancer stem-like properties and the HER2\/Akt signaling pathway in HER2-positive breast cancer","volume":"379","author":"Kim","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2017.10.020_bib40","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1101\/gad.1061803","article-title":"In\u00a0vitro propagation and transcriptional profiling of human mammary stem\/progenitor cells","volume":"17","author":"Dontu","year":"2003","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2017.10.020_bib41","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/jnci\/94.12.883","article-title":"Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us","volume":"94","author":"Hlatky","year":"2002","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2017.10.020_bib42","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1158\/0008-5472.CAN-03-1957","article-title":"Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis","volume":"64","author":"Uzzan","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2017.10.020_bib43","first-page":"879","article-title":"Validation of the 4B5 rabbit monoclonal antibody in determining Her2\/neu status in breast cancer","volume":"22","author":"van der Vegt","year":"2009","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc."},{"key":"10.1016\/j.canlet.2017.10.020_bib44","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1365-2559.2011.04034.x","article-title":"Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies","volume":"59","author":"Schrohl","year":"2011","journal-title":"Histopathology"},{"key":"10.1016\/j.canlet.2017.10.020_bib45","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ejca.2007.08.018","article-title":"Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer","volume":"43","author":"Palyi-Krekk","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2017.10.020_bib46","doi-asserted-by":"crossref","first-page":"38013","DOI":"10.1074\/jbc.M202404200","article-title":"Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase\/Akt cell survival pathway","volume":"277","author":"Ghatak","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.canlet.2017.10.020_bib47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.18632\/oncotarget.488","article-title":"Metformin-induced preferential killing of breast cancer initiating CD44+CD24-\/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts","volume":"3","author":"Cufi","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2017.10.020_bib48","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10549-015-3414-3","article-title":"CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells","volume":"151","author":"Boulbes","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2017.10.020_bib49","first-page":"185","article-title":"Flubendazole versus mebendazole in intestinal helminthic infections","volume":"39","author":"Feldmeier","year":"1982","journal-title":"Acta Trop."},{"key":"10.1016\/j.canlet.2017.10.020_bib50","volume":"vol. 31","author":"Fuchs","year":"1993"},{"key":"10.1016\/j.canlet.2017.10.020_bib51","first-page":"314","article-title":"Treatment of human alveolar echinococcosis with flubendazole. Clinical, morphological and immunological study","volume":"8","author":"Lassegue","year":"1984","journal-title":"Gastroenterologie Clinique Biol."},{"key":"10.1016\/j.canlet.2017.10.020_bib52","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4269\/ajtmh.1984.33.627","article-title":"Treatment of neurocysticercosis with flubendazole","volume":"33","author":"Tellez-Giron","year":"1984","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.canlet.2017.10.020_bib53","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrd2137","article-title":"Tumour-initiating cells: challenges and opportunities for anticancer drug discovery","volume":"8","author":"Zhou","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2017.10.020_bib54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1172\/JCI41004","article-title":"The therapeutic promise of the cancer stem cell concept","volume":"120","author":"Frank","year":"2010","journal-title":"J.\u00a0Clin. investigation"},{"key":"10.1016\/j.canlet.2017.10.020_bib55","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2007.15.1829","article-title":"Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis","volume":"26","author":"Eyler","year":"2008","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2017.10.020_bib56","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc1590","article-title":"Tumour stem cells and drug resistance","volume":"5","author":"Dean","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2017.10.020_bib57","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10549-013-2665-0","article-title":"HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer","volume":"141","author":"Lipton","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2017.10.020_bib58","doi-asserted-by":"crossref","first-page":"19063","DOI":"10.1073\/pnas.0605218103","article-title":"A\u00a0system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions","volume":"103","author":"Wehrman","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2017.10.020_bib59","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.473.65.2","article-title":"Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line","volume":"65","author":"Nagy","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2017.10.020_bib60","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1038\/onc.2013.308","article-title":"Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells","volume":"33","author":"Raina","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2017.10.020_bib61","first-page":"347","article-title":"NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer","volume":"8","author":"Molina","year":"2002","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.canlet.2017.10.020_bib62","first-page":"1196","article-title":"Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells","volume":"59","author":"Codony-Servat","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2017.10.020_bib63","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1158\/0008-5472.CAN-03-3856","article-title":"The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells","volume":"64","author":"Nahta","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2017.10.020_bib64","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2017.10.020_bib65","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.2009.24.2024","article-title":"Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy","volume":"28","author":"Baselga","year":"2010","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2017.10.020_bib66","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1200\/JCO.2011.35.6725","article-title":"Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study","volume":"30","author":"Blackwell","year":"2012","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2017.10.020_bib67","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1093\/annonc\/mdr014","article-title":"Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer","volume":"22","author":"Wu","year":"2011","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.canlet.2017.10.020_bib68","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djk134","article-title":"Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"Scaltriti","year":"2007","journal-title":"J.\u00a0Natl. Cancer Inst."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383517306572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383517306572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:39:40Z","timestamp":1759592380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383517306572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":68,"alternative-id":["S0304383517306572"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2017.10.020","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2017.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}